• OPEN AN ACCOUNT
Indian Indices
Nifty
26,033.75 47.75
(0.18%)
Sensex
85,747.83 482.51
( 0.57%)
Bank Nifty
59,288.70 -59.55
( -0.10%)
Nifty IT
38,360.25 535.00
( 1.41%)
Global Indices
Nasdaq
47,874.44 -29.46
(-0.06%)
Dow Jones
6,878.17 7.45
(0.11%)
Hang Seng
50,935.81 1,071.13
(2.15%)
Nikkei 225
9,722.32 30.25
(0.31%)
Forex
USD-INR
90.13 0.27
(0.30%)
EUR-INR
105.04 0.70
(0.67%)
GBP-INR
119.76 1.10
(0.93%)
JPY-INR
0.58 0.00
(0.57%)

EQUITY - MARKET SCREENER

Rajshree Polypack Ltd
Industry :  Packaging
BSE Code
ISIN Demat
Book Value()
535109
INE760W01023
24.190278
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
RPPL
9.6
134.68
EPS(TTM)
Face Value()
Div & Yield %
1.89
5
0
 

Zydus receives USFDA approval for Verapamil Hydrochloride Extended-Release Tablets
Nov 25,2025

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg).

Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks. Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh.

Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025).